|
US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
|
NZ227684A
(en)
|
1988-01-30 |
1991-07-26 |
Merck Sharp & Dohme |
Pyrazine, pyridazine, and pyrimidine derivatives and pharmaceutical compositions
|
|
GB9005737D0
(en)
|
1990-03-14 |
1990-05-09 |
Beecham Group Plc |
Novel compounds
|
|
FR2676444B1
(fr)
|
1991-05-16 |
1995-03-10 |
Sanofi Elf |
Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
EP1440311B1
(en)
|
2001-08-31 |
2009-01-07 |
Gen-Probe Incorporated |
Affinity-shifted probes for quantifying analyte polynucleotides
|
|
US7135484B2
(en)
|
2002-08-14 |
2006-11-14 |
Abbott Laboratories |
Azabicyclic compounds are central nervous system active agents
|
|
ATE353899T1
(de)
|
2002-09-30 |
2007-03-15 |
Neurosearch As |
Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
|
|
US8014953B2
(en)
|
2003-08-08 |
2011-09-06 |
The Regents Of The University Of California |
RNA surveillance among curated proteins
|
|
US7399765B2
(en)
|
2003-09-19 |
2008-07-15 |
Abbott Laboratories |
Substituted diazabicycloalkane derivatives
|
|
US7160876B2
(en)
|
2003-12-22 |
2007-01-09 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309699B2
(en)
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
|
US7655657B2
(en)
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US7309487B2
(en)
|
2004-02-09 |
2007-12-18 |
George Inana |
Methods and compositions for detecting and treating retinal diseases
|
|
AR049401A1
(es)
|
2004-06-18 |
2006-07-26 |
Novartis Ag |
Aza-biciclononanos
|
|
GB0415746D0
(en)
|
2004-07-14 |
2004-08-18 |
Novartis Ag |
Organic compounds
|
|
EP2380889B1
(en)
|
2004-10-07 |
2013-06-26 |
Merck Sharp & Dohme Corp. |
Thiazolyl MGLUR5 antagonists and methods for their use
|
|
KR20070073791A
(ko)
|
2004-10-18 |
2007-07-10 |
암젠 인코포레이티드 |
티아디아졸 화합물 및 이의 사용방법
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
DE602006010991D1
(de)
|
2005-01-26 |
2010-01-21 |
Schering Corp |
3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
|
|
AU2006236387A1
(en)
|
2005-04-18 |
2006-10-26 |
Neurogen Corporation |
Subtituted heteroaryl CB1 antagonists
|
|
US7598052B2
(en)
|
2005-10-11 |
2009-10-06 |
The Regents Of The University Of Michigan |
Expression profile of thyroid cancer
|
|
US8603457B2
(en)
|
2005-12-02 |
2013-12-10 |
University Of Rochester |
Nonsense suppression and genetic codon alteration by targeted modification
|
|
US7834178B2
(en)
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
MY147661A
(en)
*
|
2006-05-19 |
2012-12-31 |
Abbott Lab |
Fused bicycloheterocycle substituted azabicyclic alkane derivatives
|
|
KR101458194B1
(ko)
|
2006-05-30 |
2014-11-03 |
뉴로서치 에이/에스 |
신규한 1，4―디아자―비사이클로［3．2．2］노닐 옥사디아졸릴 유도체 및 이의 의학적 용도
|
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
US8343941B2
(en)
|
2007-03-30 |
2013-01-01 |
Rutgers, The State University Of New Jersey |
Compositions and methods for gene silencing
|
|
US8283116B1
(en)
|
2007-06-22 |
2012-10-09 |
Ptc Therapeutics, Inc. |
Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
|
|
DE102007032507A1
(de)
*
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
WO2009067579A1
(en)
|
2007-11-21 |
2009-05-28 |
Abbott Laboratories |
Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators
|
|
WO2009116353A1
(ja)
|
2008-03-18 |
2009-09-24 |
コニカミノルタホールディングス株式会社 |
電気化学的表示素子
|
|
US8633019B2
(en)
|
2008-05-27 |
2014-01-21 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
|
JP2012513409A
(ja)
|
2008-12-23 |
2012-06-14 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
|
CA2755409C
(en)
|
2009-03-16 |
2019-04-30 |
Joseph Collard |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
CA2758189C
(en)
|
2009-04-10 |
2020-12-29 |
Association Institut De Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
|
LT3449926T
(lt)
|
2009-06-17 |
2020-01-27 |
Biogen Ma Inc. |
Kompozicijos ir smn2 splaisingo subjekte moduliavimo būdai
|
|
TWI558398B
(zh)
|
2009-09-22 |
2016-11-21 |
諾華公司 |
菸鹼乙醯膽鹼受體α７活化劑之用途
|
|
EP2305679A1
(en)
|
2009-09-28 |
2011-04-06 |
GenKyoTex SA |
Pyrazoline dione derivatives as nadph oxidase inhibitors
|
|
TW201129361A
(en)
*
|
2010-01-20 |
2011-09-01 |
Abbott Lab |
Methods for treating pain
|
|
SG183146A1
(en)
|
2010-02-05 |
2012-09-27 |
Heptares Therapeutics Ltd |
1,2,4-triazine-4-amine derivatives
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
EP2560488B1
(en)
|
2010-04-23 |
2015-10-28 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
JP5889895B2
(ja)
|
2010-07-29 |
2016-03-22 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
Ａｍｐｋ活性化複素環化合物およびその使用方法
|
|
KR102090836B1
(ko)
|
2011-03-14 |
2020-03-18 |
엔에스이 프로덕츠, 인크. |
세포 정제를 촉진하기 위한 경구 제제
|
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
|
US9447075B2
(en)
|
2011-08-02 |
2016-09-20 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as EAAT2 activators
|
|
CA2853722A1
(en)
|
2011-10-27 |
2013-05-02 |
Mayo Foundation For Medical Education And Research |
Inhibiting g protein coupled receptor 6 kinase polypeptides
|
|
CN104244944B
(zh)
|
2011-12-30 |
2018-06-08 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩症的化合物
|
|
EP2809322B9
(en)
|
2012-01-26 |
2019-10-30 |
PTC Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
JP6092897B2
(ja)
|
2012-02-10 |
2017-03-08 |
ピーティーシー セラピューティクス， インコーポレイテッド |
脊髄性筋萎縮症を治療するための化合物
|
|
BR112014021531B1
(pt)
|
2012-03-01 |
2022-10-04 |
Ptc Therapeutics, Inc. |
Composto, composição farmacêutica e usos dos mesmos
|
|
EA028382B1
(ru)
|
2012-03-23 |
2017-11-30 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения спинальной мышечной атрофии
|
|
MY174339A
(en)
|
2012-08-13 |
2020-04-09 |
Novartis Ag |
1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
|
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
|
DK2906696T4
(da)
|
2012-10-15 |
2023-02-27 |
Ionis Pharmaceuticals Inc |
Fremgangsmåder til modulering af c9orf72-ekspression
|
|
WO2014111751A1
(en)
*
|
2013-01-15 |
2014-07-24 |
Novartis Ag |
Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
|
|
EP2945633B1
(en)
*
|
2013-01-15 |
2021-06-30 |
Novartis AG |
Use of alpha 7 nicotinic acetylcholine receptor agonists
|
|
JP2016508159A
(ja)
*
|
2013-01-15 |
2016-03-17 |
ノバルティス アーゲー |
アルファ７ニコチン性アセチルコリン受容体アゴニストの使用
|
|
ITMI20130063A1
(it)
*
|
2013-01-17 |
2014-07-18 |
Valier Alberto |
Dispositivo manuale per la raccolta dal suolo di frutti o altri oggetti
|
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
|
RU2673542C2
(ru)
|
2013-06-25 |
2018-11-28 |
Ф. Хоффманн-Ля Рош Аг |
Соединения для лечения спинальной мышечной атрофии
|
|
MX2020011652A
(es)
|
2013-07-31 |
2022-09-27 |
Novartis Ag |
Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
|
|
KR20160045063A
(ko)
|
2013-08-19 |
2016-04-26 |
에프. 호프만-라 로슈 아게 |
스크리닝 방법
|
|
EP3039019B1
(en)
|
2013-08-26 |
2020-04-22 |
Purdue Pharma L.P. |
Azaspiro[4.5]decane derivatives and use thereof
|
|
EP3052654A4
(en)
|
2013-09-30 |
2017-05-03 |
The Regents of the University of California |
Identification of structurally similar small molecules that enhance therapeutic exon skipping
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
ES2850999T3
(es)
|
2014-03-14 |
2021-09-02 |
Raqualia Pharma Inc |
Derivados de azaespiro como antagonistas de TRPM8
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
CA2950876A1
(en)
|
2014-06-10 |
2015-12-17 |
Erasmus University Medical Center Rotterdam |
Methods for characterizing alternatively or aberrantly spliced mrna isoforms
|
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
US20170355956A1
(en)
|
2014-09-04 |
2017-12-14 |
Rutgers, The State University Of New Jersey |
Compositions for increasing survival of motor neuron protein (smn) levels in target cells and methods of use thereof for the treatment of spinal muscular atrophy
|
|
US20170334977A1
(en)
|
2014-10-20 |
2017-11-23 |
The Brigham And Women's Hospital, Inc. |
Targeting Apolipoprotein E (APOE) in Neurologic Disease
|
|
US10053697B1
(en)
|
2015-01-09 |
2018-08-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Programmable alternative splicing devices and uses thereof
|
|
CN107257793A
(zh)
|
2015-01-20 |
2017-10-17 |
梅里亚股份有限公司 |
抗蠕虫化合物、组合物及其使用方法
|
|
EP3053577A1
(en)
|
2015-02-09 |
2016-08-10 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
|
WO2016128343A1
(en)
|
2015-02-09 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment of cancer
|
|
US10668171B2
(en)
*
|
2015-05-30 |
2020-06-02 |
Ptc Therapeutics, Inc. |
Methods for modulating RNA splicing
|
|
AU2016297558B2
(en)
|
2015-07-20 |
2021-03-25 |
Genzyme Corporation |
Colony stimulating factor-1 receptor (CSF-1R) inhibitors
|
|
US20180271803A1
(en)
|
2015-09-02 |
2018-09-27 |
Pathways Bioscience, Llc |
Compositions and methods for treatment or prevention of oral mucositis
|
|
CA2998826A1
(en)
|
2015-09-24 |
2017-03-30 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
|
US11413278B2
(en)
|
2015-10-08 |
2022-08-16 |
The Regents Of The University Of California |
Compounds and methods for promoting stress resistance
|
|
KR20220105174A
(ko)
|
2015-10-09 |
2022-07-26 |
유니버시티 오브 사우스앰톤 |
유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
|
|
EP3183347A4
(en)
*
|
2015-10-17 |
2018-04-18 |
Lifesplice Pharma LLC |
Splice modulating oligonucleotides and methods of use thereof
|
|
CA3002494C
(en)
|
2015-11-12 |
2021-01-12 |
F. Hoffmann-La Roche Ag |
Compositions for treating spinal muscular atrophy
|
|
WO2017100276A1
(en)
|
2015-12-08 |
2017-06-15 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
|
|
CN110946865B
(zh)
|
2015-12-10 |
2024-01-26 |
Ptc医疗公司 |
用于治疗亨廷顿病的方法
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
WO2017112955A1
(en)
|
2015-12-23 |
2017-06-29 |
Pharma Llc Moonshot |
Methods for inducing an immune response by inhibition of nonsense mediated decay
|
|
JP2019501979A
(ja)
|
2016-01-15 |
2019-01-24 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
Ｅａａｔ２活性化剤としてのピリダジン誘導体
|
|
EP3411080A4
(en)
|
2016-02-01 |
2019-08-14 |
Arrakis Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR TREATING RNA-MEDIATED DISEASES
|
|
EP3419981A4
(en)
|
2016-02-23 |
2019-09-18 |
Indiana University Research & Technology Corporation |
POLYTHERAPIES FOR THE TREATMENT OF SPINAL AMYOTROPHY
|
|
US11674952B2
(en)
|
2016-02-24 |
2023-06-13 |
The Rockefeller University |
Embryonic cell-based therapeutic candidate screening systems, models for Huntington's Disease and uses thereof
|
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
|
US20170268066A1
(en)
|
2016-03-15 |
2017-09-21 |
Chalmers Ventures Ab |
Cancer biomarkers
|
|
AU2017242225B2
(en)
|
2016-03-29 |
2021-02-18 |
Merck Patent Gmbh |
N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase
|
|
US10940161B2
(en)
|
2016-04-04 |
2021-03-09 |
University Of Florida Research Foundation, Incorporated |
Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
|
|
US10577360B2
(en)
|
2016-04-12 |
2020-03-03 |
Esteve Pharmaceuticals, S.A. |
Arylamide derivatives having multimodal activity against pain
|
|
RS61090B1
(sr)
|
2016-06-13 |
2020-12-31 |
Scholar Rock Inc |
Upotreba inhibitora miostatina i kombinovane terapije
|
|
RU2018145144A
(ru)
*
|
2016-07-01 |
2020-08-03 |
Арракис Терапьютикс, Инк. |
Соединения и способы для модуляции функции рнк
|
|
CA3043755A1
(en)
|
2016-11-28 |
2018-05-31 |
Ptc Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
JP7129095B2
(ja)
|
2017-02-20 |
2022-09-01 |
国立大学法人京都大学 |
スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
|
|
WO2018204412A1
(en)
|
2017-05-01 |
2018-11-08 |
Thomas Jefferson University |
Systems-level analysis of tcga cancers reveals disease trna fragmentation patterns and associations with messenger rnas and repeat
|
|
CA3065547A1
(en)
|
2017-06-14 |
2018-12-20 |
Ptc Therapeutics, Inc. |
Methods for modifying rna splicing
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
BR112019027719A2
(pt)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics, Inc. |
métodos para tratar a doença de huntington
|
|
EP3689863A1
(en)
|
2017-08-04 |
2020-08-05 |
Skyhawk Therapeutics, Inc. |
Methods and compositions for modulating splicing
|
|
JP2020534336A
(ja)
|
2017-09-20 |
2020-11-26 |
ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co., Ltd. |
Ｉｄｏ阻害剤および／またはｉｄｏ−ｈｄａｃ二重阻害剤としての多環式化合物
|
|
CA3078565A1
(en)
|
2017-10-12 |
2019-04-18 |
Revolution Medicines, Inc. |
Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
|
|
JP7381476B2
(ja)
|
2017-10-24 |
2023-11-15 |
サンガモ セラピューティクス， インコーポレイテッド |
希少疾患の処置のための方法および組成物
|
|
EP3479845A1
(en)
|
2017-11-06 |
2019-05-08 |
Stalicla S.A. |
Challenge test for diagnosing subtype of autism spectrum disease
|
|
WO2019094694A1
(en)
|
2017-11-10 |
2019-05-16 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|
|
SG11202009212WA
(en)
|
2018-03-27 |
2020-10-29 |
Ptc Therapeutics Inc |
Compounds for treating huntington's disease
|
|
KR20200142039A
(ko)
|
2018-04-10 |
2020-12-21 |
스카이호크 테라퓨틱스, 인코포레이티드 |
암 치료용 화합물
|
|
SG11202012869SA
(en)
|
2018-06-27 |
2021-01-28 |
Ptc Therapeutics Inc |
Heteroaryl compounds for treating huntington's disease
|
|
EP3814360A1
(en)
|
2018-06-27 |
2021-05-05 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
EA202092896A1
(ru)
|
2018-06-27 |
2021-04-13 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
|
|
EP3816160A4
(en)
|
2018-06-27 |
2022-03-16 |
Reborna Biosciences, Inc. |
PROPHYLACTIC OR THERAPEUTIC AGENT FOR SPINAL MUSCULAR ATROPHY
|
|
US11987568B2
(en)
|
2018-08-03 |
2024-05-21 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Allosteric inhibitor of WEE1 kinase
|
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
|
US11129829B2
(en)
*
|
2019-06-17 |
2021-09-28 |
Skyhawk Therapeutics, Inc. |
Methods for modulating splicing
|
|
CA3169709A1
(en)
|
2020-02-28 |
2021-09-02 |
Remix Therapeutics Inc. |
Heterocyclic amides and their use for modulating splicing
|
|
MX2022010681A
(es)
|
2020-02-28 |
2023-03-21 |
Remix Therapeutics Inc |
Compuestos y metodos para modular el empalme.
|
|
CA3169697A1
(en)
|
2020-02-28 |
2021-09-02 |
Dominic Reynolds |
Thiophenyl derivatives useful for modulating nucleic acid splicing
|
|
AU2021228286A1
(en)
|
2020-02-28 |
2022-10-06 |
Remix Therapeutics Inc. |
Pyridazine derivatives for modulating nucleic acid splicing
|
|
WO2021207554A1
(en)
|
2020-04-08 |
2021-10-14 |
Remix Therapeutics Inc. |
Compounds and methods for modulating splicing
|
|
MX2022012676A
(es)
|
2020-04-08 |
2023-01-11 |
Remix Therapeutics Inc |
Compuestos y metodos para modular el empalme.
|
